{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T12:41:13Z","timestamp":1776688873784,"version":"3.51.2"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study evaluated the prognostic value of a panel of 29 oncogenes derived from the analysis of The Cancer Genome Atlas (TCGA data) or from the recent literature on bladder tumors on a well-characterized series of muscle-invasive bladder cancer (MIBC) and non-MIBC (NMIBC) samples and tried to identify molecular prognostic markers. Mutations of <jats:italic>HRAS<\/jats:italic>, <jats:italic>FGFR3<\/jats:italic>, <jats:italic>PIK3CA<\/jats:italic> and <jats:italic>TERT<\/jats:italic> were found in 2.9%, 27.2%, 14.9% and 76.7% of tumor samples, respectively. Concerning NMIBC, on multivariate analysis, <jats:italic>RXRA<\/jats:italic> and <jats:italic>FGFR3<\/jats:italic> levels were associated with recurrence-free survival (RFS) (<jats:italic>p<\/jats:italic>\u2009=\u20090.0022 and <jats:italic>p<\/jats:italic>\u2009=\u20090.0069) and <jats:italic>RXRA<\/jats:italic> level was associated with progression to muscle-invasive disease (<jats:italic>p<\/jats:italic>\u2009=\u20090.0068). We identified a 3-gene molecular signature associated with NMIBC prognosis. <jats:italic>FGFR3<\/jats:italic> overexpression was associated with reduced response to Bacillus Calmette\u2013Guerin treatment (<jats:italic>p<\/jats:italic>\u2009=\u20090.037). As regards MIBC, on multivariate analysis, <jats:italic>ERCC2<\/jats:italic> overexpression was associated with RFS (<jats:italic>p<\/jats:italic>\u2009=\u20090.0011) and <jats:italic>E2F3<\/jats:italic> and <jats:italic>EGFR<\/jats:italic> overexpression were associated with overall survival (<jats:italic>p<\/jats:italic>\u2009=\u20090.014 and <jats:italic>p<\/jats:italic>\u2009=\u20090.035). RT-PCR findings were confirmed by IHC for FGFR3. Genomic alterations in MIBC revealed in TCGA data also concern NMIBC and seem to be associated with prognosis in terms of recurrence and progression. Correcting these alterations by targeted therapies seems a promising pharmacological approach.<\/jats:p>","DOI":"10.1038\/s41598-020-73642-8","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T10:04:27Z","timestamp":1601978667000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Assessment of prognostic implication of a panel of oncogenes in bladder cancer and identification of a 3-gene signature associated with recurrence and progression risk in non-muscle-invasive bladder cancer"],"prefix":"10.1038","volume":"10","author":[{"given":"Constance","family":"Le Goux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Vacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Schnitzler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Barry Delongchamps","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Zerbib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Peyromaure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathilde","family":"Sibony","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Allory","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Bieche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Damotte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geraldine","family":"Pignot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,6]]},"reference":[{"key":"73642_CR1","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature12965","volume":"507","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315\u2013322 (2014).","journal-title":"Nature"},{"key":"73642_CR2","doi-asserted-by":"publisher","first-page":"e0127908","DOI":"10.1371\/journal.pone.0127908","volume":"10","author":"F Massari","year":"2015","unstructured":"Massari, F. et al. Prognostic value of beta-tubulin-3 and c-Myc in muscle invasive urothelial carcinoma of the bladder. PLoS ONE 10, e0127908 (2015).","journal-title":"PLoS ONE"},{"key":"73642_CR3","doi-asserted-by":"publisher","first-page":"5808","DOI":"10.1158\/0008-5472.CAN-14-1531","volume":"74","author":"Y-P Fu","year":"2014","unstructured":"Fu, Y.-P. et al. The 19q12 bladder cancer GWAS signal: association with cyclin E function and aggressive disease. Cancer Res. 74, 5808\u20135818 (2014).","journal-title":"Cancer Res."},{"key":"73642_CR4","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.bulcan.2015.10.004","volume":"102","author":"G Pignot","year":"2015","unstructured":"Pignot, G., le Goux, C. & Bieche, I. Recent advances in bladder urothelial carcinogenesis. Bull. Cancer (Paris) 102, 1020\u20131035 (2015).","journal-title":"Bull. Cancer (Paris)"},{"key":"73642_CR5","doi-asserted-by":"publisher","first-page":"12458","DOI":"10.3390\/ijms150712458","volume":"15","author":"S Salvi","year":"2014","unstructured":"Salvi, S. et al. Copy number analysis of 24 oncogenes: MDM4 identified as a putative marker for low recurrence risk in non muscle invasive bladder cancer. Int. J. Mol. Sci. 15, 12458\u201312468 (2014).","journal-title":"Int. J. Mol. Sci."},{"key":"73642_CR6","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1093\/hmg\/dds486","volume":"22","author":"SV Williams","year":"2013","unstructured":"Williams, S. V., Hurst, C. D. & Knowles, M. A. Oncogenic FGFR3 gene fusions in bladder cancer. Hum. Mol. Genet. 22, 795\u2013803 (2013).","journal-title":"Hum. Mol. Genet."},{"key":"73642_CR7","doi-asserted-by":"publisher","first-page":"42183","DOI":"10.18632\/oncotarget.5619","volume":"6","author":"MK Kiessling","year":"2015","unstructured":"Kiessling, M. K. et al. Mutant HRAS as novel target for MEK and mTOR inhibitors. Oncotarget 6, 42183\u201342196 (2015).","journal-title":"Oncotarget"},{"key":"73642_CR8","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson, A. G. et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171, 540-556.e25 (2017).","journal-title":"Cell"},{"key":"73642_CR9","doi-asserted-by":"publisher","first-page":"e30862","DOI":"10.7554\/eLife.30862","volume":"6","author":"AM Halstead","year":"2017","unstructured":"Halstead, A. M. et al. Bladder-cancer-associated mutations in RXRA activate peroxisome proliferator-activated receptors to drive urothelial proliferation. eLife 6, e30862 (2017).","journal-title":"eLife"},{"key":"73642_CR10","doi-asserted-by":"publisher","first-page":"6987","DOI":"10.1158\/0008-5472.CAN-17-1701","volume":"77","author":"JT Goldstein","year":"2017","unstructured":"Goldstein, J. T. et al. Genomic activation of PPARG reveals a candidate therapeutic axis in bladder cancer. Cancer Res. 77, 6987\u20136998 (2017).","journal-title":"Cancer Res."},{"key":"73642_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-017-00147-w","volume":"8","author":"M Korpal","year":"2017","unstructured":"Korpal, M. et al. Evasion of immunosurveillance by genomic alterations of PPAR\u03b3\/RXR\u03b1 in bladder cancer. Nat. Commun. 8, 1\u201314 (2017).","journal-title":"Nat. Commun."},{"key":"73642_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14808","author":"DG Ward","year":"2019","unstructured":"Ward, D. G. et al. Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratification. BJU Int. https:\/\/doi.org\/10.1111\/bju.14808 (2019).","journal-title":"BJU Int."},{"key":"73642_CR13","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41585-018-0001-5","volume":"15","author":"C G\u00fcnes","year":"2018","unstructured":"G\u00fcnes, C. et al. Implications of TERT promoter mutations and telomerase activity in urothelial carcinogenesis. Nat. Rev. Urol. 15, 386\u2013393 (2018).","journal-title":"Nat. Rev. Urol."},{"key":"73642_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12746","author":"Y Hayashi","year":"2020","unstructured":"Hayashi, Y. et al. TERT C228T mutation in non-malignant bladder urothelium is associated with intravesical recurrence for patients with non-muscle invasive bladder cancer. Mol. Oncol. https:\/\/doi.org\/10.1002\/1878-0261.12746 (2020).","journal-title":"Mol. Oncol."},{"key":"73642_CR15","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3390\/ijms21030947","volume":"21","author":"R Batista","year":"2020","unstructured":"Batista, R. et al. TERT promoter mutation as a potential predictive biomarker in BCG-treated bladder cancer patients. Int. J. Mol. Sci. 21, 947 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"73642_CR16","doi-asserted-by":"publisher","first-page":"17426","DOI":"10.1073\/pnas.1310522110","volume":"110","author":"PS Rachakonda","year":"2013","unstructured":"Rachakonda, P. S. et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc. Natl. Acad. Sci. 110, 17426\u201317431 (2013).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"73642_CR17","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00345-007-0213-4","volume":"25","author":"MA Knowles","year":"2007","unstructured":"Knowles, M. A. Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target. World J. Urol. 25, 581\u2013593 (2007).","journal-title":"World J. Urol."},{"key":"73642_CR18","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.3892\/ol.2015.3691","volume":"10","author":"C Poyet","year":"2015","unstructured":"Poyet, C. et al. Positive fibroblast growth factor receptor 3 immunoreactivity is associated with low-grade non-invasive urothelial bladder cancer. Oncol. Lett. 10, 2753\u20132760 (2015).","journal-title":"Oncol. Lett."},{"key":"73642_CR19","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature13385","volume":"511","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543\u2013550 (2014).","journal-title":"Nature"},{"key":"73642_CR20","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.euf.2018.02.013","volume":"5","author":"A Necchi","year":"2019","unstructured":"Necchi, A. et al. Prognostic effect of FGFR mutations or gene fusions in patients with metastatic urothelial carcinoma receiving first-line platinum-based chemotherapy: results from a large, single-institution cohort. Eur. Urol. Focus 5, 853\u2013856 (2019).","journal-title":"Eur. Urol. Focus"},{"key":"73642_CR21","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.juro.2015.06.093","volume":"195","author":"YV Langle","year":"2016","unstructured":"Langle, Y. V. et al. FGFR3 down-regulation is involved in bacillus Calmette\u2013Gu\u00e9rin induced bladder tumor growth inhibition. J. Urol. 195, 188\u2013197 (2016).","journal-title":"J. Urol."},{"key":"73642_CR22","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0176","author":"AJ Vandeveer","year":"2016","unstructured":"Vandeveer, A. J. et al. Systemic immunotherapy of non-muscle invasive mouse bladder cancer with avelumab, an anti-PD-L1 immune checkpoint inhibitor. Cancer Immunol. Res. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0176 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"73642_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.02.3005","author":"NM Donin","year":"2016","unstructured":"Donin, N. M. et al. Immunotherapy in the treatment of urothelial carcinoma. J. Urol. https:\/\/doi.org\/10.1016\/j.juro.2016.02.3005 (2016).","journal-title":"J. Urol."},{"key":"73642_CR24","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1158\/1078-0432.CCR-16-2267","volume":"23","author":"NM Hahn","year":"2017","unstructured":"Hahn, N. M. et al. A phase II trial of dovitinib in BCG-unresponsive urothelial carcinoma with FGFR3 mutations or overexpression: hoosier cancer research network trial HCRN 12-157. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 23, 3003\u20133011 (2017).","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"73642_CR25","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1200\/JCO.19.02044","volume":"38","author":"J Rosenberg","year":"2020","unstructured":"Rosenberg, J. et al. EV-101: a phase I study of single-agent enfortumab vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma. J. Clin. Oncol. 38, 1041\u20131049 (2020).","journal-title":"J. Clin. Oncol."},{"key":"73642_CR26","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/ng.687","volume":"42","author":"N Rothman","year":"2010","unstructured":"Rothman, N. et al. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat. Genet. 42, 978\u2013984 (2010).","journal-title":"Nat. Genet."},{"key":"73642_CR27","doi-asserted-by":"publisher","first-page":"244ra91","DOI":"10.1126\/scitranslmed.3008970","volume":"6","author":"S Rebouissou","year":"2014","unstructured":"Rebouissou, S. et al. EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Sci. Transl. Med. 6, 244ra91 (2014).","journal-title":"Sci. Transl. Med."},{"key":"73642_CR28","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.1200\/JCO.2012.41.9572","volume":"30","author":"Y-N Wong","year":"2012","unstructured":"Wong, Y.-N. et al. Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 30, 3545\u20133551 (2012).","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"73642_CR29","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1001\/jamaoncol.2016.1056","volume":"2","author":"D Liu","year":"2016","unstructured":"Liu, D. et al. Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma. JAMA Oncol. 2, 1094\u20131096 (2016).","journal-title":"JAMA Oncol."},{"key":"73642_CR30","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3390\/ijms20040793","volume":"20","author":"J Tse","year":"2019","unstructured":"Tse, J., Ghandour, R., Singla, N. & Lotan, Y. Molecular predictors of complete response following neoadjuvant chemotherapy in urothelial carcinoma of the bladder and upper tracts. Int. J. Mol. Sci. 20, 793 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"73642_CR31","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1158\/1078-0432.CCR-18-1001","volume":"25","author":"Q Li","year":"2019","unstructured":"Li, Q. et al. ERCC2 helicase domain mutations confer nucleotide excision repair deficiency and drive cisplatin sensitivity in muscle-invasive bladder cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 25, 977\u2013988 (2019).","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"73642_CR32","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.eururo.2018.09.002","volume":"75","author":"EJ Pietzak","year":"2019","unstructured":"Pietzak, E. J. et al. Genomic differences between \u2018primary\u2019 and \u2018secondary\u2019 muscle-invasive bladder cancer as a basis for disparate outcomes to cisplatin-based neoadjuvant chemotherapy. Eur. Urol. 75, 231\u2013239 (2019).","journal-title":"Eur. Urol."},{"key":"73642_CR33","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/path.4886","volume":"242","author":"G Sj\u00f6dahl","year":"2017","unstructured":"Sj\u00f6dahl, G., Eriksson, P., Liedberg, F. & H\u00f6glund, M. Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification. J. Pathol. 242, 113\u2013125 (2017).","journal-title":"J. Pathol."},{"key":"73642_CR34","unstructured":"Sobin, L., Gospodarowicz, M. & Wittekind, C. TNM classification of malignant tumors. In UICC International Union Against Cancer 262\u20135 (2006)."},{"key":"73642_CR35","first-page":"7","volume":"16","author":"V Molini\u00e9","year":"2006","unstructured":"Molini\u00e9, V. Classification of bladder tumors in 2006. Prog. Urol. FMC 16, 7\u201310 (2006).","journal-title":"Prog. Urol. FMC"},{"key":"73642_CR36","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.eururo.2008.05.027","volume":"56","author":"G Pignot","year":"2009","unstructured":"Pignot, G. et al. Large-scale real-time reverse transcription-PCR approach of angiogenic pathways in human transitional cell carcinoma of the bladder: identification of VEGFA as a major independent prognostic marker. Eur. Urol. 56, 678\u2013688 (2009).","journal-title":"Eur. Urol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73642-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73642-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73642-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T20:33:10Z","timestamp":1670358790000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73642-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,6]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["73642"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-73642-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,6]]},"assertion":[{"value":"11 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16641"}}